Viatris Inc.

VTRS Healthcare Drug Manufacturers Specialty & Generic

Viatris Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, down 2.98% from fiscal 2024.

Revenue
−0.28%
EPS
−154.6%
Free cash flow
+38.8%
Total debt
−89.4%

Quarter to September 2026, against a year earlier

19.76 0.79 +4.16%
Market cap
$21.8B
P/E
0.0×
Fwd P/E
82.6×
Dividend yield
2.54%
F-score
4/9
Altman Z
0.61
Beneish M
−3.29
Dividend safety
37/100

Viatris Inc. (VTRS) P/B ratio

Alert me on P/B ratio

As of 5 November 2026, Viatris Inc. (VTRS) trades at a P/B ratio of 1.6×. Over the past ten years it has ranged from 0.4× (March 2021) to 7.4× (March 2015); the current reading is higher than 75% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 1.8× and below the Healthcare sector median of 2.3×.

P/B ratio, daily

Embed this chart

Annual newest first

Period P/B ratio Change
FY2025 1.0× 24.27%
FY2024 0.8× 19.34%
FY2023 0.7× 2.05%
FY2022 0.7× (17.98%)
FY2021 0.8× 62.61%
FY2020 0.5× (43.73%)
FY2019 0.9× (24.72%)
FY2018 1.2× (33.09%)
FY2017 1.7× (4.06%)
FY2016 1.8× (30.97%)

Quarterly newest first

Period P/B ratio Change
Sep 2026 1.5× 16.27%
Jun 2026 1.3× 21.65%
Mar 2026 1.1× 7.49%
Dec 2025 1.0× 30.77%
43 more quarters

Against its own ten years

Low 0.4× High 7.4×
Ten-year median 0.8×
Current reading's percentile 82

P/B ratio against peers

What P/B ratio is

Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.

Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))

The full definition of P/B ratio →

More on VTRS